Align Technology, Inc. ALGN SPXR3KPHARMA
Company Overview
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Why Investors Should Care
Net profit has compounded at 10.8% per year over the last five years.
Revenue has grown at a 17.5% CAGR over the past five years.
Operating margin of 18.2% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.03B (+0.9% YoY); net profit $410.35M.
- Trailing 12 Months Year-on-year growth — revenue +4.3%, earnings -12.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.5%, profit CAGR 10.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.54% |
| 1 Year: | 4.30% |
Compounded Profit Growth
| 5 Years: | 10.76% |
| 1 Year: | -12.10% |
Stock Price Performance
| 1 Year: | +8.85% |
| 6 Months: | -8.83% |
| 3 Months: | -5.43% |
| 1 Month: | -6.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.76 · Neutral
P/E of 27.59 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.5% over 5 years.
- Profit CAGR of 10.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALGN Align Technology, Inc. SPXR3KPHARMA | 158.64 | 27.59 | $11.27B | 0.00% | 13.57% | 10.15% | 17.54% | 10.76% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 436.92M | 490.26M | 505.29M | 548.97M | 600.70M | 607.34M | 550.96M | 352.31M | 734.14M | 894.77M | 1.01B | 1.02B | 973.22M | 969.55M | 890.35M | 943.15M | 1.00B | 960.21M | 997.43M | 1.03B | - | - | 979.26M | 1.01B | 995.69M | 1.05B | 1.04B | 1.06B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 299.15M | 304.33M | 356.49M | 363.97M | 303.50M | - |
| Gross Profit | 137.25M | 145.48M | 145.05M | 151.09M | 158.63M | 157.58M | 180.63M | 205.22M | 209.20M | 235.62M | 270.92M | 292.49M | 327.41M | 365.58M | 371.78M | 402.10M | 432.29M | 437.55M | 394.36M | 224.33M | 534.09M | 677.10M | 758.54M | 755.16M | 709.35M | 687.56M | 619.17M | 660.65M | 713.61M | 663.08M | 697.82M | 722.63M | - | - | 680.11M | 708.12M | 639.20M | 683.59M | 736.59M | 757.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 544.83M | 545.08M | 511.08M | 524.71M | 564.00M | - |
| Operating Income | 41.80M | 48.73M | 51.55M | 48.92M | 42.33M | 38.05M | 53.33M | 65.14M | 62.08M | 61.67M | 83.57M | 98.76M | 98.19M | 122.69M | 125.21M | 87.70M | 176.49M | 127.15M | 69.92M | -73.00M | 177.07M | 225.45M | 268.90M | 261.16M | 198.08M | 188.20M | 143.66M | 133.52M | 171.93M | 166.35M | 154.13M | 147.05M | - | - | 135.28M | 163.03M | 128.12M | 158.88M | 172.59M | 154.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 174.43M | 203.61M | 183.84M | 260.87M | 229.13M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.44M | 173.52M | 94.73M | 176.59M | 148.89M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.21M | 48.91M | 37.98M | 40.84M | 36.12M | - |
| Net Income | 32.44M | 35.60M | 38.25M | 36.18M | 31.35M | 27.62M | 40.55M | 50.15M | 51.37M | 69.42M | 69.18M | 82.56M | 95.87M | 106.11M | 100.87M | 71.85M | 147.14M | 102.52M | 1.52B | -40.60M | 139.37M | 200.38M | 199.71M | 180.97M | 134.30M | 112.80M | 72.70M | 87.80M | 111.81M | 121.43M | 105.03M | 96.56M | - | - | 93.23M | 124.61M | 56.75M | 135.76M | 112.77M | 108.29M |
| Diluted EPS | 0.39 | 0.43 | 0.47 | 0.44 | 0.39 | 0.34 | 0.50 | 0.62 | 0.63 | 0.85 | 0.85 | 1.01 | 1.17 | 1.30 | 1.24 | 0.89 | 1.83 | 1.28 | 19.21 | -0.52 | 1.76 | 2.51 | 2.51 | 2.28 | 1.70 | 1.44 | 0.93 | 1.14 | 1.46 | 1.58 | 1.39 | 1.28 | - | - | 1.27 | 1.72 | 0.78 | 1.89 | 1.57 | 1.51 |
| R&D Expense | 13.38M | 13.29M | 12.85M | 13.88M | 15.68M | 17.78M | 15.08M | 18.61M | 20.41M | 22.80M | 24.38M | 24.20M | 29.59M | 30.80M | 32.70M | 37.50M | 38.85M | 39.68M | 41.53M | 40.36M | 44.53M | 54.54M | 57.72M | 65.59M | 71.81M | 72.97M | 76.97M | 87.45M | 88.48M | 88.74M | 91.86M | 92.19M | 85.27M | - | 97.20M | 96.40M | 93.28M | - | 98.66M | 102.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 303.98M | 312.33M | 387.13M | 479.74M | 560.04M | 660.21M | 761.65M | 845.49M | 1.08B | 1.47B | 1.97B | 2.41B | 2.47B | - | 3.73B | 3.86B | 4.00B | 4.03B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10B | 1.16B | 1.20B | 1.32B |
| Gross Profit | 225.13M | 233.49M | 303.42M | 361.28M | 416.39M | 498.11M | 578.44M | 640.11M | 815.29M | 1.12B | 1.45B | 1.74B | 1.76B | - | 2.63B | 2.71B | 2.80B | 2.71B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98B | 2.05B | 2.13B | 2.13B |
| Operating Income | 15.51M | -34.01M | 102.73M | 90.36M | 85.59M | 94.21M | 193.58M | 188.63M | 248.92M | 353.61M | 466.56M | 542.49M | 387.17M | - | 654.05M | 656.65M | 671.76M | 585.31M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 779.84M | 799.05M | 816.80M | 822.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 599.06M | 641.20M | 608.96M | 585.29M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.48M | 196.15M | 187.60M | 174.94M |
| Net Income | 79.99M | -31.27M | 74.25M | 66.72M | 58.69M | 64.30M | 145.83M | 144.02M | 189.68M | 231.42M | 400.24M | 442.78M | 1.78B | - | 361.57M | 445.05M | 421.36M | 410.35M |
| Diluted EPS | 1.18 | -0.45 | 0.95 | 0.83 | 0.71 | 0.78 | 1.77 | 1.77 | 2.33 | 2.83 | 4.92 | 5.53 | 22.41 | - | 4.61 | 5.81 | 5.62 | 5.65 |
| R&D Expense | 26.16M | 22.25M | 26.00M | 37.15M | 42.87M | 44.08M | 52.80M | 61.24M | 75.72M | 97.56M | 128.90M | 157.36M | 175.31M | 250.31M | 305.26M | 346.83M | 364.20M | 369.91M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 355.24M | 476.94M | 649.26M | 756.31M | 832.15M | 988.00M | 1.16B | 1.40B | 1.78B | 2.05B | 2.50B | 4.83B | - | 5.95B | 6.08B | 6.21B | 6.23B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.42B | 2.45B | 2.49B | 2.62B |
| Cash & Equivalents | 89.12M | 87.10M | 166.49M | 294.66M | 306.39M | 306.39M | 242.95M | 199.87M | 167.71M | 389.27M | 449.51M | 636.90M | 550.42M | 960.84M | - | 942.05M | 937.44M | 1.04B | 1.09B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 338.75M | 296.90M | 254.29M | 226.34M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 859.68M | 903.42M | 995.68M | 1.10B |
| Total Liabilities | - | - | 82.20M | 99.20M | 158.48M | 175.00M | 198.18M | 235.23M | 310.71M | 400.76M | 629.72M | 799.57M | 1.15B | 1.60B | - | 2.35B | 2.45B | 2.36B | 2.18B |
| Current Liabilities | - | - | 81.24M | 92.97M | 148.12M | 155.77M | 175.34M | 201.81M | 271.67M | 354.33M | 500.05M | 692.07M | 970.97M | 1.33B | - | 1.93B | 2.07B | 2.04B | 1.92B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.91M | 126.62M | 119.28M | 114.45M |
| Total Equity | 161.15M | 218.54M | 377.75M | 377.75M | 490.78M | 581.32M | 633.97M | 752.77M | 847.93M | 999.31M | 1.15B | 1.25B | 1.35B | 3.23B | - | 3.60B | 3.63B | 3.85B | 4.05B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.27M | 75.08M | 73.85M | 71.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 39.75M | 74.17M | 129.53M | 130.47M | 133.78M | 185.98M | 226.90M | 238.00M | 247.65M | 438.54M | 554.68M | 747.27M | 662.17M | - | 568.73M | 785.78M | 738.23M | 593.22M |
| Investing Cash Flow | -1.05M | -1.56M | -15.92M | -211.61M | -78.30M | -210.73M | -201.63M | -166.36M | 73.03M | -251.48M | 6.93M | -350.44M | -231.51M | - | -213.32M | -195.94M | -254.91M | -112.44M |
| Financing Cash Flow | -40.35M | 6.84M | 14.71M | 27.24M | 10.21M | -38.17M | -66.42M | -100.79M | -95.52M | -135.50M | -369.43M | -485.54M | -30.81M | - | -501.69M | -598.34M | -355.72M | -464.58M |
| Capital Expenditure | -14.33M | -7.19M | -18.03M | -30.40M | -38.33M | -19.41M | -24.09M | -53.45M | -70.58M | -195.69M | -223.31M | -149.71M | -154.92M | - | -291.90M | -177.72M | -115.58M | -102.44M |
| Free Cash Flow | 25.41M | 66.97M | 111.50M | 100.06M | 95.44M | 166.56M | 202.81M | 184.55M | 177.08M | 242.84M | 331.37M | 597.56M | 507.26M | - | 276.83M | 608.06M | 622.65M | 490.78M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -146.27M | -8.51M | 127.60M | 16.20M |
| Share Buybacks | 50.14M | - | 0 | 7.75M | 47.20M | 95.11M | 98.23M | 101.79M | 96.22M | 103.79M | 300.00M | 400.00M | 0 | 375.04M | 435.04M | 592.36M | 352.88M | 465.94M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.1% | 74.8% | 78.4% | 75.3% | 74.3% | 75.4% | 75.9% | 75.7% | 75.5% | 75.8% | 73.6% | 72.5% | 71.3% | - | 70.5% | 70.1% | 70.0% | 67.2% |
| Operating Margin % | 5.1% | -10.9% | 26.5% | 18.8% | 15.3% | 14.3% | 25.4% | 22.3% | 23.1% | 24.0% | 23.7% | 22.5% | 15.7% | - | 17.5% | 17.0% | 16.8% | 14.5% |
| Net Margin % | 26.3% | -10.0% | 19.2% | 13.9% | 10.5% | 9.7% | 19.1% | 17.0% | 17.6% | 15.7% | 20.4% | 18.4% | 71.8% | - | 9.7% | 11.5% | 10.5% | 10.2% |
| ROE % | 36.6% | -8.3% | 19.7% | 13.6% | 10.1% | 10.1% | 19.4% | 17.0% | 19.0% | 20.0% | 31.9% | 32.9% | 54.9% | - | 10.0% | 12.3% | 10.9% | 10.1% |
| ROCE % | - | -12.4% | 26.8% | 18.0% | 14.3% | 14.3% | 24.6% | 21.3% | 23.9% | 27.5% | 34.3% | 35.5% | 11.0% | - | 16.3% | 16.3% | 16.1% | 13.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.17% | 4.42M | $696.40M |
| 2 | Vanguard Capital Management LLC | 6.15% | 4.40M | $693.56M |
| 3 | FMR, LLC | 5.67% | 4.06M | $639.78M |
| 4 | Capital International Investors | 5.65% | 4.05M | $637.50M |
| 5 | Capital World Investors | 4.78% | 3.42M | $539.30M |
| 6 | Goldman Sachs Group Inc | 4.71% | 3.37M | $531.48M |
| 7 | Vanguard Portfolio Management LLC | 4.37% | 3.13M | $493.50M |
| 8 | State Street Corporation | 3.57% | 2.56M | $403.17M |
| 9 | Geode Capital Management, LLC | 3.14% | 2.25M | $353.82M |
| 10 | Ninety One UK Ltd | 3.09% | 2.21M | $348.22M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALGN
Has Align Technology (ALGN) Fallen Far Enough To Look Undervalued?
Align Technology stock has delivered a steeply negative 5 year share price performance, yet current valuation checks suggest the market price may now be below what its cash flows imply. At the same time, traditional market multiples look ro…
What Does Align Technology (ALGN) Gain From Its Board Change?
Align Technology (NasdaqGS:ALGN) appoints Quentin Blackford of iRhythm Technologies to its board of directors. Andrea L. Saia plans to resign from Align Technology's board after serving for more than a decade. The board change introduces ne…
Align Technology (ALGN) Could Be 24% Undervalued On Mixed Earnings Guidance
Align Technology (ALGN) is back in focus after its latest earnings report, which met revenue expectations and exceeded earnings forecasts, while also including softer guidance amid pricing and economic pressures across the sector. Align Tec…
2 of Wall Street’s Favorite Stocks with Exciting Potential and 1 We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about comp…
Q2 Earnings Outperformers: Align Technology (NASDAQ:ALGN) And The Rest Of The Dental Equipment & Technology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Align Technology (NASDAQ:ALGN) and its peers.
Quentin Blackford to Join Align Technology Board of Directors
TEMPE, Ariz. & SAN JOSE, Calif., August 31, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scan…
ALGN — Frequently Asked Questions
What is the current share price of Align Technology, Inc. (ALGN)?
As of 2026-09-07 16:24 PDT, Align Technology, Inc. (ALGN) trades at $158.64 on NasdaqGS. Its 52-week range is $124.88 to $197.51.
What is the market capitalisation of ALGN?
Align Technology, Inc. (ALGN) has a market capitalisation of $11.27B on NasdaqGS.
What is the P/E ratio of ALGN?
ALGN trades at a trailing price-to-earnings (P/E) ratio of 27.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.93.
What is the return on equity (ROE) of ALGN?
ALGN has a return on equity (ROE) of 10.15%. Its return on capital employed (ROCE) is 13.57%.
Is ALGN a good stock to buy?
This page provides a data-driven analysis of Align Technology, Inc. (ALGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.